News about Global Pharma

Ractigen Therapeutics Secures FDA Orphan Drug Designation for RAG-21

RAG-21 is an siRNA therapy specifically designed to target FUS-ALS, one of the most aggressive subtypes of ALS.

Global Pharma | 20/11/2024 | By Aishwarya |  807

Samsung Biologics Announces Manufacturing Deal with European Pharmaceutical Company

Samsung Biologics is set to add antibody-drug conjugate (ADC) services to its portfolio, with a dedicated facility to be completed by the end of this year.

Global Pharma | 20/11/2024 | By Aishwarya |  435

NRx Pharmaceuticals Welcomes Michael Abrams as Chief Financial Officer

Abrams succeeds Interim-CFO Richard Narido, who will continue to support the Company's financial function and other projects.

Global Pharma | 19/11/2024 | By Aishwarya |  399

Telix Plans to Add FAP-Targeting Candidates to Theranostic Pipeline

Telix has entered into asset purchase and exclusive worldwide in-licence agreements for a suite of clinically validated FAP-targeting therapeutic and precision medicine (diagnostic) radiopharmaceutical candidates.

Global Pharma | 19/11/2024 | By Aishwarya |  723

Indegene Inaugurates New Center in Hyderabad to Empower Global Business

This move aligns with Indegene’s purpose to enable healthcare organizations to be future-ready by combining deep medical expertise with fit-for-purpose technology.

Global Pharma | 18/11/2024 | By Aishwarya |  701

AbbVie Receives European Commission Approval of ELAHERE

ELAHERE is the first and only folate receptor alpha (FR?)-directed antibody drug conjugate (ADC) medicine approved in the European Union (EU), as well as Iceland, Liechtenstein, Norway, and Northern Ireland.

Global Pharma | 18/11/2024 | By Aishwarya |  502

Ascentage Pharma Gets NDA Approval for Bcl-2 Inhibitor Lisaftoclax

This NDA is based on results from a pivotal registrational Phase II study in China (APG2575CC201) that evaluated the efficacy and safety of lisaftoclax in patients with r/r CLL/SLL.

Global Pharma | 18/11/2024 | By Aishwarya |  529

Pulmatrix Proposes Merger Deal with Cullgen

Cullgen utilizes its proprietary technology platform, uSMITE™, featuring novel E3 ligands, to build the next generation of targeted protein degraders and degrader-antibody conjugates (DACs).

Global Pharma | 16/11/2024 | By Aishwarya |  462

DBT, BIRAC Unveil Webinar Series on Biomanufacturing and Biofoundry Initiative

The webinar series aims to bring together industry leaders, scientists, researchers, start-ups, and SMEs to discuss key developments in biomanufacturing.

Global Pharma | 16/11/2024 | By Aishwarya |  317

Alembic Pharmaceuticals Gets USFDA Final Approval for Ivabradine Tablets

Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.

Global Pharma | 15/11/2024 | By Aishwarya |  373